FAP PET/CT scans of the lungs in adults with tuberculosis
Tests [18F]-FAPI-74 PET/CT scans to look for lung scarring in tuberculosis.
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 10 people, planned
- Started
- 22 Sept 2026
- Expected to end
- 30 Sept 2030
- Type of study
- Interventional
- Treatments tested
- [18F]-FAPI-74
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung tuberculosis (TB) confirmed by a lab test, who are starting or already on standard TB treatment and have cavities in the lungs on chest X-ray.
- Age
- 21 years or older
- Sex
- All sexes can join.
- Disease stage
- Lung TB confirmed by culture or Xpert MTB/RIF PCR on a respiratory sample, with cavity disease on the chest X-ray score.
- Earlier treatment
- Must be on, or able to start, standard drug-sensitive TB treatment. Cannot have had at least 7 days of corticosteroids or any other systemic investigational agent within 3 months before enrolment.
- Biomarker or test result
- A positive culture or Xpert MTB/RIF PCR test on at least one respiratory sample.
Main reasons for not taking part
- TB resistant to rifampin, or TB only outside the lungs
- Pregnant or breast-feeding women
- Major other lung disease such as asthma, COPD or interstitial lung disease
- Cannot tolerate the imaging scans
- Symptoms or signs suggesting active TB at pre-screening, or any condition that could harm safety or taking part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Participants will be ≥ 21 years of age
- Diagnosed with microbiologically confirmed (culture or Xpert MTB/RIF PCR positive on at least one respiratory sample) pTB
- Be currently on or able to initiate standard drug-sensitive pTB treatment according to IDSA guidelines
- Have initiated or planning to initiate TB treatment prior to screening and enrollment
- Have a Timika CXR score indicating cavitary disease
- Be able and willing to provide written informed consent to participate in the study
Who cannot take part
- Have been administered at least 7 days of corticosteroids or any duration of another systemic investigational agent within 3 months of enrollment per medical record review or patient self-report
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study, including completion of the study follow-up or TB treatment
- History of major alternative pulmonary disease such as asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease as per medical record review or patient self-report. "Major" is defined as potentially resulting in pulmonary radiographic abnormalities that could interfere with interpretation of PET-CT scan data
- Diagnosed with TB that is resistant to rifampin per medical record review or have only extrapulmonary TB
- Women of childbearing potential may not be pregnant or breast-feeding. A negative pregnancy test will be required before [F-18]-FAPI-74 injection
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
- Have symptoms or signs that, in the opinion of the investigative team, are suggestive of active TB at the time of pre-screening per patient self-report
Where in United States
- Perelman School of Medicine, Nuclear MedicinePhiladelphia, United StatesContact: Erin SchubertTaking people
About the trial
What the trial wants to find out
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis. The Investigators propose to use FAP PET/CT to define the extent and location of FAP signals in lungs of TB patients early in TB treatment and after TB cure. These timepoints are chosen as they could be utilized to deliver treatments designed to prevent, predict, or treat Post-transplant Lymphoproliferative Disorder (PTLD). The overarching hypothesis is that greater FAP signals in lungs of adult TB patients are associated with greater imaging manifestations of PTLD after cure.
The group in the trial
- Pulmonary Tuberculosis CohortTreatment being tested
Participants aged 21 years of age or older with a diagnosis of pulmonary Tuberculosis
Treatment: [18F]-FAPI-74
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
- Plain-language title
- FAP PET/CT scans of the lungs in adults with tuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 November 2026